1-17 of 17
David I. Quinn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer

Xinyi Zhou, Yohei Sekino, Hong-Tao Li, Guanghou Fu, Zhi Yang, Shuqing Zhao, Hemant Gujar, Xiongbing Zu, Daniel J. Weisenberger, Inderbir S. Gill, Varsha Tulpule, Anishka D’souza, David I. Quinn, Bo Han, Gangning Liang
Journal: Cancer Research
Cancer Res (2023) 83 (22): 3813–3826.
https://doi.org/10.1158/0008-5472.CAN-23-0401
Published: 15 November 2023
View article titled, <em>SETD2</em> Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer
Open the PDF for <em>SETD2</em> Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 3736: SETD2 aberrancy enhanced the synergetic anti-tumor effects of DNA hypomethylating agents and PARP inhibitors in aggressive clear cell renal cell carcinoma

Xinyi Zhou, Guanghou Fu, Hong-Tao Li, Hemant Gujar, Daniel J. Weisenberger, David I. Quinn, Bo Han, Gangning Liang
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3736.
https://doi.org/10.1158/1538-7445.AM2022-3736
Published: 15 June 2022
View article titled, Abstract 3736: SETD2 aberrancy enhanced the synergetic anti-tumor effects of DNA hypomethylating agents and PARP inhibitors in aggressive clear cell renal cell carcinoma
Journal Articles

Abstract CT121: A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy

Elizabeth R. Plimack, Kerry Campbell, Jean-Pierre J. Issa, Noah M. Hahn, David I. Quinn, Hyo Sik Jang, Galen Hostetter, Peter W. Nichols, Woonbok Chung, Jozef Madzo, Hitoshi Ohtani, Hui Shen, Toshinori Hinoue, Stephen B. Baylin, Peter A. Jones
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT121.
https://doi.org/10.1158/1538-7445.AM2021-CT121
Published: 01 July 2021
View article titled, Abstract CT121: A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy
Journal Articles

Abstract 2188: Urothelial cancer-GENOmic analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study

Jeffrey S. Damrauer, Jeff Klomp, Wolfgang Beck, Mi Zhou, Elizabeth Plimack, Matthew Galsky, Petros Grivas, Noah Hahn, Peter O'Donnell, Gopa Iyer, David I. Quinn, Katherine A. Hoadley, William Y. Kim, Matthew I. Milowsky
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2188.
https://doi.org/10.1158/1538-7445.AM2021-2188
Published: 01 July 2021
View article titled, Abstract 2188: Urothelial cancer-GENOmic analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study
Journal Articles

Abstract 3139: EphB4-EphrinB2 receptor-ligand are downstream effectors and novel targets of PTEN deficient prostate cancer

Grace X. Li, Binyun Ma, Valery G. Krasnoperov, Imran Siddiqi, Akash Sali, Gangning Liang, Inderbir S. Gill, Jacek K. Pinski, David I. Quinn, Sarmad Sadeghi, Parkash S. Gill
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3139.
https://doi.org/10.1158/1538-7445.AM2019-3139
Published: 01 July 2019
View article titled, Abstract 3139: EphB4-EphrinB2 receptor-ligand are downstream effectors and novel targets of PTEN deficient prostate cancer
Journal Articles

Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study

Toni K. Choueiri, David I. Quinn, Tian Zhang, Howard Gurney, Gurjyot K. Doshi, Patrick Wayne Cobb, Francis Parnis, Jae-Lyun Lee, Se Hoon Park, Andrey Semenov, Antoine Thiery-Vuillemin, Piotr Sawrycki, Piotr Tomczak, Boris Alekseev, Adel Izmailov, Wayne Yen-Hwa Chang, Shuyan M. Wan, Christian Heinrich Poehlein, Jaqueline Willemann-Rogerio, Thomas Powles
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT162.
https://doi.org/10.1158/1538-7445.AM2019-CT162
Published: 01 July 2019
View article titled, Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study
Journal Articles

Abstract CT001: Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study

David M. Hyman, Sarina A. Piha-Paul, Jordi Rodon, Cristina Saura, Geoffrey I. Shapiro, David I. Quinn, Victor Moreno, Ingrid A. Mayer, Carlos Arteaga, Valentina Boni, Emiliano Calvo, Sherene Loi, Albert C. Lockhart, Lillian M. Smyth, Joseph Erinjeri, Maurizio Scaltriti, Gary Ulaner, Jean Torrisi, Juber Patel, Jiabin Tang, Fanli Meng, Duygu Selcuklu, Helen Won, Nancy Bouvier, Michael F. Berger, Richard E. Cutler, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Alshad S. Lalani, Richard P. Bryce, Funda Meric-Bernstam, José Baselga, David B. Solit
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT001.
https://doi.org/10.1158/1538-7445.AM2017-CT001
Published: 01 July 2017
View article titled, Abstract CT001: Neratinib in <em>HER2</em> or <em>HER3</em> mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
Journal Articles

Abstract CT015: Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870)

Roberto Pili, David I. Quinn, Hans J. Hammers, J. Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Dominick Lamonica, Alan Hutson, Adrienne Groman, Susan M. Perkins, Richard Piekarz, Michael Carducci
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT015.
https://doi.org/10.1158/1538-7445.AM2016-CT015
Published: 15 July 2016
View article titled, Abstract CT015: Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870)
Journal Articles

Abstract 1587: Targeted sequencing of prostate cancer circulating tumor cells in comparison with matched cell free DNA and prostate tumors

Brian Hu, Stephen Liu, Yucheng Xu, Paul Dempsey, William Strauss, Kristopher Wentzel, Tong Xu, Jacek Pinski, Tanya Dorff, Jessamine Winer-Jones, David I. Quinn, Amir Goldkorn
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1587.
https://doi.org/10.1158/1538-7445.AM2015-1587
Published: 01 August 2015
View article titled, Abstract 1587: Targeted sequencing of prostate cancer circulating tumor cells in comparison with matched cell free DNA and prostate tumors
Journal Articles

Abstract LB-227: Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) and matched primary tumors.

Stephen V. Liu, Paul W. Dempsey, William Strauss, Yucheng Xu, Tong Xu, Jessamine Winer-Jones, Tim J. Triche, David I. Quinn, Janine McMurdie, Andre Defusco, Amir Goldkorn
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-227.
https://doi.org/10.1158/1538-7445.AM2013-LB-227
Published: 15 April 2013
View article titled, Abstract LB-227: Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) and matched primary tumors.
Journal Articles

EphB4 Expression and Biological Significance in Prostate Cancer

Guangbin Xia, S. Ram Kumar, Rizwan Masood, Sutao Zhu, Ramchandra Reddy, Valery Krasnoperov, David I. Quinn, Susan M. Henshall, Robert L. Sutherland, Jacek K. Pinski, Siamak Daneshmand, Maurizio Buscarini, John P. Stein, Chen Zhong, Daniel Broek, Pradip Roy-Burman, Parkash S. Gill
Journal: Cancer Research
Cancer Res (2005) 65 (11): 4623–4632.
https://doi.org/10.1158/0008-5472.CAN-04-2667
Published: 01 June 2005
View article titled, EphB4 Expression and Biological Significance in Prostate Cancer
Open the PDF for EphB4 Expression and Biological Significance in Prostate Cancer in another window
Journal Articles

Survival Analysis of Genome-Wide Gene Expression Profiles of Prostate Cancers Identifies New Prognostic Targets of Disease Relapse

Susan M. Henshall, Daniel E. H. Afar, Jordan Hiller, Lisa G. Horvath, David I. Quinn, Krishan K. Rasiah, Kurt Gish, Dorian Willhite, James G. Kench, Margaret Gardiner-Garden, Phillip D. Stricker, Howard I. Scher, John J. Grygiel, David B. Agus, David H. Mack, Robert L. Sutherland
Journal: Cancer Research
Cancer Res (2003) 63 (14): 4196–4203.
Published: 21 July 2003
View article titled, Survival Analysis of Genome-Wide Gene Expression Profiles of Prostate Cancers Identifies New Prognostic Targets of Disease Relapse
Open the PDF for Survival Analysis of Genome-Wide Gene Expression Profiles of Prostate Cancers Identifies New Prognostic Targets of Disease Relapse in another window
Journal Articles

Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer

Lisa G. Horvath, Susan M. Henshall, C-Soon Lee, Darren R. Head, David I. Quinn, Sari Makela, Warick Delprado, David Golovsky, Phillip C. Brenner, Gordon O’Neill, Raji Kooner, Phillip D. Stricker, John J. Grygiel, Jan-Ake Gustafsson, Robert L. Sutherland
Journal: Cancer Research
Cancer Res (2001) 61 (14): 5331–5335.
Published: 01 July 2001
View article titled, Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer
Open the PDF for Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer in another window
Journal Articles

Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer

Susan M. Henshall, David I. Quinn, C. Soon Lee, Darren R. Head, David Golovsky, Phillip C. Brenner, Warick Delprado, Phillip D. Stricker, John J. Grygiel, Robert L. Sutherland
Journal: Cancer Research
Cancer Res (2001) 61 (2): 423–427.
Published: 01 January 2001
View article titled, Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer
Open the PDF for Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer in another window
Journal Articles

Prognostic Significance of p53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy

David I. Quinn, Susan M. Henshall, Darren R. Head, David Golovsky, J. David Wilson, Phillip C. Brenner, Jennifer J. Turner, Warick Delprado, John F. Finlayson, Phillip D. Stricker, John J. Grygiel, Robert L. Sutherland
Journal: Cancer Research
Cancer Res (2000) 60 (6): 1585–1594.
Published: 01 March 2000
View article titled, Prognostic Significance of p53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy
Open the PDF for Prognostic Significance of p53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy in another window
Journal Articles

Elevated Levels of Peritumoral Chondroitin Sulfate Are Predictive of Poor Prognosis in Patients Treated by Radical Prostatectomy for Early-Stage Prostate Cancer

Carmela Ricciardelli, David I. Quinn, Wendy A. Raymond, Kieran McCaul, Peter D. Sutherland, Phillip D. Stricker, John J. Grygiel, Robert L. Sutherland, Villis R. Marshall, Wayne D. Tilley, David J. Horsfall
Journal: Cancer Research
Cancer Res (1999) 59 (10): 2324–2328.
Published: 15 May 1999
View article titled, Elevated Levels of Peritumoral Chondroitin Sulfate Are Predictive of Poor Prognosis in Patients Treated by Radical Prostatectomy for Early-Stage Prostate Cancer
Open the PDF for Elevated Levels of Peritumoral Chondroitin Sulfate Are Predictive of Poor Prognosis in Patients Treated by Radical Prostatectomy for Early-Stage Prostate Cancer in another window
Journal Articles

Granulosa Cell Tumors Express erbB4 and Are Sensitive to the Cytotoxic Action of Heregulin-β2/PE40

Christophe Furger, Rodney J. Fiddes, David I. Quinn, Ron J. Bova, Roger J. Daly, Robert L. Sutherland
Journal: Cancer Research
Cancer Res (1998) 58 (9): 1773–1778.
Published: 01 May 1998
View article titled, Granulosa Cell Tumors Express erbB4 and Are Sensitive to the Cytotoxic Action of Heregulin-β2/PE40
Open the PDF for Granulosa Cell Tumors Express erbB4 and Are Sensitive to the Cytotoxic Action of Heregulin-β2/PE40 in another window